MG

Markus Goebel

Biotech & Medtech consulting

Einsiedeln, Schwyz

Advisor

Invests in

Stages:

Seed
Pre-seed

Sectors:

BioTech

Locations:

  • Min Investment:

    $0.00

  • Max Investment:

    $0.00

  • Target Investment:

    $0.00

Skills

Pharmaceutical Industry
Venture Capital
Biotechnology
Life Sciences
Oncology
Biopharmaceuticals

Education

Investments

Merganser Biotech

Series A

Total Funding: $28M

Sorbent Therapeutics

Series B

Total Funding: $86M

Work Experience

OSE Immunotherapeutics

2024

  • Director

    2024

    OSE Immunotherapeutics is an integrated biotechnology company dedicated to developing First-In-Class Immunotherapies in Immuno-Inflammation (I&I) and Immuno-Oncology (I-O).

Innosuisse

2022

  • Expert

    2022

hemotune AG

2022

  • Director

    2022

    hemotune AG is a pioneering Swiss biotech company based on nanoengineered magnetic beads and its breakthrough technology platform with multiple application possibilities. It has recently closed a CHF 14m Series B to advance the lead program into the clinic.

M&G Advisors GmbH

2019

  • Founder & CEO

    2019

    Biotech and MedTech consulting

HAYA Therapeutics SA

2020 - 2020

  • Director

    2020 - 2020

    HAYA Therapeutics is a Swiss-based pre-clinical early stage biopharmaceutical company dedicated to treating fibrotic diseases through the discovery and development of innovative targeted first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.

Novartis Venture Fund

2004 - 2019

  • Managing Director

    2004 - 2019

    • Managing Director Novartis Venture Fund (NVF) 2004-2019 (US & EU) • Investments: Sirtris (sirtuins), FoldRx (protein misfolding), Locus (in-silico drug design), Trellis (human MAbs), LigoCyte (vaccines), Visiogen (IOL device; co-lead), Ra Pharma (cyclic peptides), Sorbent (polymer for CHF), Intellikine (PI3K/mTOR pathway), Avila (covalent sm; co-lead), eFFECTOR (protein translation), merganser (hepcidin mimetics), AlloCyte (LFA-1 inhibitors), Expansion (repeat mRNA; co-lead), Ribon (monoPARPs) • Key investment contributions: Ablation Frontiers (AF device), Proteostasis (protein networks), Sonitus (hearing device) • Exits: IPO: Sirtris, Proteostasis, Ra Pharma; M&A: FoldRx (Pfizer), Ablation Frontiers (Medtronic), Visiogen (Abbott), Intellikine (Takeda), Avila (Celgene), LigoCyte (Takeda)

Novartis

2000 - 2004

  • Head Pharma Corporate M&A

    2002 - 2004

    Acquisitions and divestments in and out of Novartis AG

  • Head Nervous System BD&L Pharma

    2000 - 2002

    Licensing options for Novartis Pharma in Nervous System

Roche

1992 - 1999

  • Several Marketing & Strategy positions incl. an alliance with Amgen

    1992 - 1999

    Head of Strategic Portfolio Management & Life Cycle Planning Pharma Senior Business Analyst Strategic Unit Pharma International Medical & Registration Manager Neupogen® (in co-operation with AMGEN)

FARMITALIA CARLO ERBA LIMITED

1990 - 1992

  • Medical Manager Oncology & Medical Science

    1990 - 1992